James Richey, MD
Urology · Alexandria, LANPI 1649243767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.
Across 384 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$890
- Endo Pharmaceuticals Inc.$602
- Sumitomo Pharma America, Inc.$531
- Johnson & Johnson$441
- Urovant Sciences Inc$281
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,34897%
- Education$2083%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,368 |
| Astellas Pharma US Inc | 52 | $890 |
| Endo Pharmaceuticals Inc. | 56 | $602 |
| Sumitomo Pharma America, Inc. | 26 | $531 |
| Johnson & Johnson(2 entities) | 26 | $441 |
| Urovant Sciences Inc | 20 | $281 |
| Antares Pharma, Inc. | 17 | $258 |
| Myriad Genetic Laboratories, Inc. | 12 | $241 |
| Pfizer | 15 | $232 |
| Blue Earth Diagnostics | 10 | $205 |
| Tolmar, Inc. | 7 | $168 |
| Coloplast | 5 | $147 |
| Tolmar Pharmaceuticals, Inc. | 9 | $143 |
| Bayer | 7 | $137 |
| Endo USA, Inc. | 7 | $122 |
| Ferring Pharmaceuticals Inc. | 6 | $115 |
| Neotract Inc. | 4 | $80 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $76 |
| Progenics Pharmaceuticals, Inc. | 2 | $67 |
| Cook Medical LLC | 2 | $57 |
| Acerus Pharmaceuticals Corporation | 3 | $42 |
| Accord Healthcare, Inc. | 2 | $40 |
| Zyla Life Sciences, Inc. | 2 | $40 |
| Hollister Incorporated | 2 | $36 |
| Teleflex LLC | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Medtronic | 2 | $26 |
| Myovant Sciences Inc. | 1 | $25 |
| Procept Biorobotics Corporation | 1 | $22 |
| Halozyme Inc | 1 | $21 |
| Calyxo, Inc. | 1 | $19 |
| 180 Medical, Inc. | 1 | $18 |
| Dentsply IH Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
How this compares
$6,556 in reported general payments places this provider in the 70th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 271 | $183,873 |
| MyrbetriqMirabegron | 71 | $52,280 |
| ElmironPentosan Polysulfate Sodium | 17 | $36,499 |
| Tamsulosin Hcl | 949 | $10,400 |
| Finasteride | 666 | $10,325 |
| XyostedTestosterone Enanthate | 16 | $9,487 |
| NitrofurantoinNitrofurantoin Macrocrystal | 249 | $7,293 |
| Trimethoprim | 70 | $6,037 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 226 | $4,825 |
| Dutasteride | 174 | $4,309 |
| Cefpodoxime Proxetil | 47 | $3,671 |
| Solifenacin Succinate | 158 | $2,768 |
| Estradiol | 41 | $2,582 |
| Testosterone Cypionate | 74 | $2,259 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 72 | $1,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $531 | $183,873271 claims |
| Astellas Pharma US IncMyrbetriq | $890 | $52,28071 claims |
| Antares Pharma, Inc.Xyosted | $258 | $9,48716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 199 urology providers in Louisiana.
Other urology in Alexandria
- Joshua HolsteadAlexandria$7K
- Robert FontaneAlexandria$6K
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Sunil PurohitCovington$99K
- Raju ThomasNew Orleans$67K
- Louis KraneNew Orleans$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.